Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mercaptopurine PK and Toxicity in Pediatric ALL
NCT03920813Phase 4Unknown
- Sponsor
- Shandong University
- Start
- Jan 2015
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of mercaptopurine in acute lymphoblastic leukemia (ALL), sponsored by Shandong University. Primary endpoints: Red blood cells (RBC) concentration of 6-mercaptopurine (6-MP) at Day 2 and Genetic polymorphisms in Chinese patients with ALL at Day 2. Status: unknown.
02
Drugs
mercaptopurine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03920813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920813.